Date: 2015-01-06
Type of information: Series D financing round
Company: Seres Health (USA - MA)
Investors: Nestlé Health Science (Switzerland)
Amount: $ 65 million
Funding type: series D financing round
Planned used: Nestlé Health Science’s investment will help fund the next stage of development of Seres Health’s oral microbiome therapeutic, SER-109, for preventing the recurrence of Clostridium difficile infection (CDI), into Phase 3 clinical trials as well as the advancement of the company’s pipeline of therapeutics to treat other diseases of the human microbiome. Last July, Seres Health has completed enrollment for its single-arm, open-label clinical trial of SER-109. SER-109 is rationally designed to restore the microbiome of CDI patients to a state of health and thereby prevent recurrences. Preliminary data from the trial demonstrates the prevention of CDI recurrence in 29 of the 30 patients enrolled.
Others: *On January 6, 2015, Nestlé Health Science has completed a $65 million Series D preferred stock investment in Seres Health Inc., based in Cambridge. Seres Health is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat diseases by restoring the function of a dysbiotic microbiome. Advances in genomics are progressively revealing the importance of the microbiome, which comprise around 100 trillion microorganisms that live in the body, to various aspects of health. Seres Health is developing a pipeline of Ecobiotic® therapeutic product candidates, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. The Seres Health pipeline is relevant to Nestlé Health Science’s focus to develop novel therapeutic approaches for gastrointestinal, metabolic, brain disorders and other health conditions.
Therapeutic area: Infectious diseases - Inflammatory diseases - Metabolic diseases
